Research Overview
The Rev-Erb target
REV-ERBα and REV-ERBβ are ligand-regulated nuclear receptors whose natural ligand is heme. Unlike most nuclear receptors they lack the activation function domain needed to recruit coactivators, so they act purely as repressors, binding RORE elements and recruiting the NCoR-HDAC3 complex. Because BMAL1 is one of their principal targets, agonists that increase Rev-Erb activity shift both clock gene expression and the metabolic programmes the clock coordinates.
- Amplitude and phase of circadian gene expression in liver, muscle and adipose tissue
- Locomotor and sleep-architecture changes in mice, including reduced wakefulness bouts
- Mitochondrial content and oxidative gene expression in skeletal muscle
- Plasma lipid and glucose parameters and adiposity in diet-challenged rodents
- Macrophage inflammatory gene expression and, in later work, viability of transformed cell lines
The off-target caveat
A 2019 study reported that SR9009 produced several of its characteristic cellular effects in cells genetically lacking both Rev-Erb receptors, indicating that a portion of the observed activity is receptor-independent. Because SR9011 is a close analog frequently used interchangeably in the same experiments, the same question applies to it, and current work in this area is expected to include genetic controls rather than relying on pharmacology alone.
Pharmacokinetic limits
Rodent work has reported low oral bioavailability and rapid clearance for this compound series, which is why in-vivo studies typically use parenteral administration and frequent dosing intervals. Any inference from cell-culture concentrations to whole-animal exposure has to account for that, and comparisons across studies are unreliable when the route differs.
